Knight Therapeutics | GUD - Sales Revenues

Stock Price
6.22
Daily Change
0.05 0.81%
Monthly
-3.42%
Yearly
-0.80%
Q1 Forecast
5.95

Knight Therapeutics reported CAD121.55M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Acasti Pharma USD -4.76M 4.76M Dec/2024
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
Alaunos Therapeutics USD 2K 2K Mar/2025
Aurora Cannabis CAD 94.19M 3.82M Dec/2025
Avita Medical AUD 17.61M 805K Dec/2025
Canopy Growth CAD 66.68M 5.45M Sep/2025
Cronos Group USD 58.39M 22.05M Dec/2025
Dianthus Therapeutics USD 284K 112K Dec/2025
Ionis Pharmaceuticals USD 203M 46M Dec/2025
IQVIA Holdings USD 4.36B 260M Dec/2025
Knight Therapeutics CAD 121.55M 14.19M Sep/2025
Moderna USD 678M 342M Dec/2025
Organigram Holdings CAD 80.06M 9.27M Sep/2025
Organon & Co USD 1.51B 90M Dec/2025
Revvity USD 772.06M 73.06M Dec/2025
Tectonic Therapeutic USD 0 0 Dec/2024
Tilray USD 217.51M 74.75M Dec/2025
Viatris USD 3.7B 60M Dec/2025
Xeris Pharmaceuticals USD 85.81M 11.43M Dec/2025